Thomas L. Chenevert

(734) 936-8866

Biological Sciences, Healthcare Research
Image Data, Machine Learning, Statistics
Relevant Projects:

Thomas L. Chenevert


Radiology, Michigan Medicine

Collegiate Professor of Basic Radiological Sciences, Professor of Radiology and Program Assistant, Lab Supervisor, Radiology, Medical School

Multi-center clinical trials increasingly utilize quantitative diffusion imaging (DWI) to aid in patient management and treatment response assessment for translational oncology applications. A major source of systematic bias in diffusion was discovered originating from platform-dependent gradient hardware. Left uncorrected, these biases confound quantitative diffusion metrics used for characterization of tissue pathology and treatment response leading to inconclusive findings, and increasing the requisite subject numbers and trial cost. We have developed technology to mitigate systematic diffusion mapping bias that exists on MRI scanners and are in process of deploying this technology for multi-center clinical trials. Another major source of variance and bottleneck in high-throughput analysis of quantitative diffusion maps is segmentation of tumor/tissue volume of interest (VOI) based on intensities and patterns on multi-contrast MR image datasets, as well as reliable assessment of longitudinal change with disease progression or response to treatment. Our goal is development/trial/application AI algorithms for robust (semi-) automated VOI definition in analysis of multi-dimensional MR datasets for oncology trials.

Representative apparent diffusion coefficient (ADC) histograms and map overlays are shown for oncology trials to be supported by this Academic Industrial Partnership (AIP). ADC is used to characterize tumor malignancy of breast cancer, therapeutic effect in head and neck (H&N) and cellular proliferation in bone marrow of myelofibrosis (MF) patients. Relevant clinical outcome metrics are illustrated under histograms for detection sensitivity threshold (to reduce unnecessary breast biopsies (13)), Kaplan-Meier analysis of therapy response (stratified by median SD of H&N metastatic node (23)), and histopathologic proliferation stage (MF cellular infiltration classification).